ASX Share rice
Fri 14 Aug 2020 - 08:59:pm (Sydney)

PXS Share Price

PHARMAXIS LTDPXSPharmaceuticals, Biotechnology & Life Sciences

PXS Company Information

Name:

Pharmaxis Ltd

Sector:

Healthcare

Industry:

Drug Manufacturers—General

GIC Industry:

Pharmaceuticals

GIC Sub Industry:

Pharmaceuticals

Address:

20 Rodborough Road Frenchs Forest Australia 2086

Phone:

61 2 9454 7200

CEO, MD & Director:

Mr. Gary Jonathan Phillips

CFO & Company Sec.:

Mr. David Morris McGarvey BA, CA, CPA

Head of Drug Discovery:

Dr. Wolfgang G. Jarolimek Ph.D., B.Sc. Ph.D.

Gen. Counsel:

Mr. Cameron David Billingsley

Head of Chemistry for Drug Discovery:

Dr. Dieter Hamprecht

Company Overview:

Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Bronchitol and Aridol Business, and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, a lung function test used to diagnose and manage asthma by detecting active airway inflammation through measuring airway hyper-responsiveness. The company's drug discovery programs include amine oxidase drug platform programs, such as semicarbazide-sensitive amine oxidase (SSAO) inhibitor BI 1467335 for the treatment of inflammation; selective LOXL2 inhibitor for NASH, pulmonary fibrosis, liver, and kidney fibrosis; LOX inhibitor for scaring and cancer; and other SSAO/MPO inhibitor programs. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.

PXS Share Price Information

Shares Issued:

395.03M

Market Capitalisation:

$43.45M

Revenue (TTM):

$12.67M

Revenue Per Share (TTM):

$0.03

Earnings per Share:

$-0.053

Profit Margin:

-1.1009

Operating Margin (TTM):

$-1.25

Return On Assets (TTM):

$-0.22

Return On Equity (TTM):

$-1.72

Quarterly Revenue Growth (YOY):

0.01

Gross Profit(TTM):

$11.21M

Diluted Earnings Per Share (TTM):

$-0.053

PXS CashFlow Statement

CashFlow Date:

2020-06-30

Change To Liabilities:

$0

Total Cashflow From Investing Activities:

$-574,000

Total Cash From Operating Activities:

$-13,284,000

Other Cashflow From Investing Activities:

$-574,000

Capital Expenditures:

$0

PXS Income Statement

Income Date:

2020-06-30

Other Operating Expenses:

$1.65M

PXS Balance Sheet

Balance Sheet Date:

2020-06-30

Common Stock:

$1.43M

Other Liabilities:

$23.07M

Other Assets:

$2.76M

Property - Plant & Equipment:

$8.91M

Net Tangible Assets:

$1.43M

PXS Share Price History

PXS News

15 Apr, 2020
This month, we saw the Pharmaxis Ltd (ASX:PXS) up an impressive 40%. But that isn't much consolation to those who have...
04 Nov, 2019
Gary Phillips has been the CEO of Pharmaxis Ltd (ASX:PXS) since 2013. This report will, first, examine the CEO...